Literature DB >> 19373552

A retrospective study of quality of life in a community sample of patients with early stage breast cancer.

Mark S Walker1, Lee S Schwartzberg, Edward J Stepanski, Barry V Fortner.   

Abstract

Few studies have examined the pattern of change in quality of life (QoL) over time among patients with breast cancer, or the impact of disease recurrence on QoL. This retrospective study examined QoL among patients with stage I-IIIB breast cancer. Individual, disease and treatment characteristics were abstracted from the medical record, and linked with QoL data collected as a routine part of patient care. The sample included patients with nonrecurrent (N = 100) and recurrent (N = 19) disease, who completed 1,449 QoL assessments. Linear mixed model analysis showed that disease recurrence significantly and adversely affected QoL across all domains. QoL did not appear to deteriorate before recurrence. The pattern of adjustment after recurrence varied across QoL domains in theoretically consistent ways. Study findings suggest that patients show improvement in some areas after recurrence, but generally do not recover previous levels of QoL.

Entities:  

Mesh:

Year:  2009        PMID: 19373552     DOI: 10.1007/s10549-009-0387-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Real-world outcomes in patients with unresected stage III non-small cell lung cancer.

Authors:  Kellie J Ryan; Karen E Skinner; Ancilla W Fernandes; Rajeshwari S Punekar; Melissa Pavilack; Mark S Walker; Noam A VanderWalde
Journal:  Med Oncol       Date:  2019-01-31       Impact factor: 3.064

2.  Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Authors:  Mark S Walker; Edward J Stepanski; Carolina Reyes; Sacha Satram-Hoang; Arthur C Houts; Lee S Schwartzberg
Journal:  Ther Adv Hematol       Date:  2011-06

3.  Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer.

Authors:  Mark S Walker; Elaine Yu Pharm; Jiandong Kerr; Yeun Mi Yim; Edward J Stepanski; Lee S Schwartzberg
Journal:  BMC Res Notes       Date:  2012-06-20

4.  Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.

Authors:  Mark S Walker; Murad Hasan; Yeun Mi Yim; Elaine Yu; Edward J Stepanski; Lee S Schwartzberg
Journal:  Health Qual Life Outcomes       Date:  2011-06-20       Impact factor: 3.186

5.  Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.

Authors:  Himani Aggarwal; Rajeshwari S Punekar; Li Li; Gebra Cuyun Carter; Mark S Walker
Journal:  Health Qual Life Outcomes       Date:  2020-06-22       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.